Eclipse Therapeutics, Inc.
Eclipse Therapeutics, Inc. (“Eclipse”) is a biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells and other forms of innovative cancer treatment. Eclipse is leveraging its deep expertise in cancer stem cell biology and therapeutic antibodies to develop novel therapeutics that address unmet needs in cancer patient care.
Acquired by Bionomics Ltd (ASX:BNO) in 2012
Independa, Inc. provides an integrated platform to help caregivers help their loved ones stay at home longer, safer and more comfortably. Independa delivers technology-enabled independent living products and services for the rapidly growing population of nearly 50 million family caregivers supporting elderly loved ones. Independa provides an integrated, cost-effective and real-time answer to the key question, “How is my loved one doing?”
Inhibrx is a biotherapeutics discovery and development company with an extensive internally developed biotherapeutics pipeline focused on cancer, inflammatory and metabolic diseases. The Inhibrx business model allows early risk sharing with pharmaceutical partners and creatively implements multiple development strategies to enhance program success rates, achieve rapid execution and produce optimal clinical candidates.
Ignyta, Inc. (NASDAQ: RXDX), a biotechnology company focused on precision medicine in oncology, works tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by companion diagnostic (Dx) tests. The company’s integrated Rx/Dx strategy allows them to enter uncharted territory, illuminating the molecular drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with the rarest cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With their pipeline of potentially first-in-class or best-in-class precision medicines, Ignyta is pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.
Became public in 2013 (NASDAQ: RXDX)
Medenovo is an entrepreneurial medical device venture focused on bringing innovation to medical device value creation.
Flex Pharma, Inc.
Flex Pharma, Inc. (NASDAQ: FLKS) is a biotechnology company that is developing innovative and proprietary treatments for cramps and spasms associated with the severe neurological diseases of ALS, MS, and peripheral neuropathies, such as Charcot-Marie-Tooth (CMT).
Became public in 2015 (NASDAQ: FLKS)
Patara Pharma, LLC
Patara Pharma is a clinical-stage biopharmaceutical company developing new therapeutics that significantly improve the lives of patients suffering from chronic inflammatory lung diseases and immune disorders. The company’s lead candidate, PA101, is an anti-inflammatory therapeutic delivered via a proprietary aerosol device. Patara has completed a Phase 2a clinical trial with positive results and is now planning a robust Phase 2b study for the treatment of refractory chronic cough in patients diagnosed with idiopathic pulmonary fibrosis, an orphan disease with no curative therapy.
Bonti is a rapidly emerging biotechnology enterprise founded by world class neurotoxin experts with proven success at Allergan, the originator of Botox®. The company’s focus is on developing novel treatment paradigms driven by its unique neurotoxin platform. Bonti is targeting both aesthetic and therapeutic indications with strong unmet needs not currently addressed by existing marketed products. The lead product candidate, EB-001, is a botulinum neurotoxin which has a mechanism of action similar to currently marketed neurotoxin products, but with a differentiated clinical profile that enables it to address multibillion dollar market opportunities.